Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy

Medical Science Monitor

Volumn 20, Issue , 2014, Pages 1376-1382

  Lin, Ying Li ^a   Xie, Pei Gen ^b   Wang, Li ^c   Ma, Jian Guo ^d  

^a JIANGSU UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c HEBEI UNIVERSITY OF ENGINEERING   (China)

^d HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Cadherins; DNA methylation; Urologic neoplasms

Indexed keywords

CADHERIN; PROTOCADHERIN 17; UNCLASSIFIED DRUG; PRIMER DNA; PROSTATE SPECIFIC ANTIGEN; PROTOCADHERIN 17, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; DNA EXTRACTION; DNA METHYLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; RECURRENCE FREE SURVIVAL; TRANSURETHRAL RESECTION; BLOOD; CHINA; DIAGNOSTIC USE; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CADHERINS; CHINA; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA PRIMERS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905583243     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.891247     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. Cancer J Clin, 2013; 63(1): 11-30
2. Zhang H, Qi C, Li L et al: Clinical significance of NUCB2 mRNA expression in prostate cancer. J Exp Clin Cancer Res, 2013; 32(1): 56
3. Zhang H, Cheng S, Wang A et al: Expression of RABEX-5 and its clinical significance in prostate cancer. J Exp Clin Cancer Res, 2014; 33: 31
4. Ren SC, Chen R, Sun YH: Prostate cancer research in China. Asian J Androl, 2013; 15(3): 350-53
5. Chiam K, Ricciardelli C, Bianco-Miotto T: Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett, 2014; 342(2): 248-56
6. Efthimiou I, Skrepetis K, Bournia E: Single Foci Prostate Cancer: Current Diagnosis and Management. Curr Urol, 2013; 7(1): 1-6
7. Dimakakos A, Armakolas A, Koutsilieris M: Novel Tools for Prostate Cancer Prognosis, Diagnosis, and Follow-Up. Biomed Res Int, 2014; 2014: 890697
8. Ragsdale JW, Halstater B, Martinez-Bianchi V: Prostate Cancer Screening. Prim Care, 2014; 41(2): 355-70
9. Pan J, Chen Y, Mo C et al: Association of DSC3 mRNA down-regulation in prostate cancer with promoter hypermethylation and poor prognosis. PLoS One, 2014; 9(3): e92815
10. Hung AY, Levy L, Kuban DA: Stage T1c prostate cancer: a heterogeneous category with widely varying prognosis. Cancer J, 2002; 8(6): 440-44
11. Salesi N, Carlini P, Ruggeri EM et al: Prostate cancer: the role of hormonal therapy. J Exp Clin Cancer Res, 2005; 24(2): 175-80
12. Chao C, Chi M, Preciado M et al: Methylation markers for prostate cancer prognosis: a systematic review. Cancer Causes Control, 2013; 24(9): 1615-41
13. Jerónimo C, Henrique R: Epigenetic biomarkers in urological tumors: A systematic review. Cancer Lett, 2014; 342(2): 264-74
14. Neuhausen A, Florl AR, Grimm MO et al: DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther, 2006; 5(8): 993-1001
15. van Roy F: Beyond E-cadherin: roles of other cadherin superfamily members in cancer. Nat Rev Cancer, 2014; 14(2): 121-34
16. Costa VL, Henrique R, Danielsen SA et al: TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics, 2011; 6(9): 1120-30
17. Giefing M, Zemke N, Brauze D et al: High resolution ArrayCGH and expression profiling identifies PTPRD andPCDH17/PCH68 as tumor suppressor gene candidates in laryngeal squamous cell carcinoma. Genes Chromosomes Cancer, 2011; 50(3): 154-66
18. Yang Y, Liu J, Li X et al: PCDH17 gene promoter demethylation and cell cycle arrest by genistein in gastric cancer. Histol Histopathol, 2012; 27(2): 217-24
19. Hu X, Sui X, Li L et al: Protocadherin 17 acts as a tumour suppressor inducing tumour cell apoptosis and autophagy, and is frequently methylated in gastric and colorectal cancers. J Pathol, 2013; 229(1): 62-73
20. Wang XB, Lin YL, Li ZG et al: Protocadherin 17 promoter methylation in tumour tissue from patients with bladder transitional cell carcinoma. J Int Med Res, 2014; 42(2): 292-99
21. Luo ZG, Li ZG, Gui SL et al: Protocadherin-17 promoter methylation in serum-derived DNA is associated with poor prognosis of bladder cancer. J Int Med Res, 2014; 42(1): 35-41
22. Kramer SA, Spahr J, Brendler CB et al: Experience with Gleason's histopathologic grading in prostatic cancer. J Urol, 1980; 124(2): 223-25
23. Bagnall P: Diagnosis and treatment of prostate cancer. Nurs Times, 2014; 110(9): 12-15
24. Dubhashi SP, Kumar H, Nath SR: Prostate cancer presenting as cervical lymphadenopathy. Am J Case Rep, 2012; 13: 206-8
25. Bryniarski P, Paradysz A, Fryczkowski M: PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monit, 2011; 17(2): CR104-9
26. Stein M, Goodin S, Doyle-Lindrud S et al: Transdermal estradiol in castrate and chemotherapy resistant prostate cancer. Med Sci Monit, 2012; 18(4): CR260-64
27. Ho A, Gabriel A, Bhatnagar A et al: Seasonality pattern of breast, colorectal, and prostate cancer is dependent on latitude. Med Sci Monit, 2014; 20: 818-24
28. Knight SJ: Decision making and prostate cancer screening. Urol Clin North Am, 2014; 41(2): 257-66
29. Yu JS, Koujak S, Nagase S et al: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene, 2008; 27(34): 4657-65
30. Li Z, Chim JC, Yang M et al: Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta, 2012; 1823(2): 298-305
31. Imoto I, Izumi H, Yokoi S et al: Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res, 2006; 66(9): 4617-26
32. Kim SY, Yasuda S, Tanaka H et al: Non-clustered protocadherin. Cell Adh Migr, 2011; 5(2): 97-105
33. Lin YL, Ma JH, Luo XL et al: Clinical significance of protocadherin-8 (PCDH8) promoter methylation in bladder cancer. J Int Med Res, 2013; 41(1): 48-54
34. Zhang D, Zhao W, Liao X et al: Frequent silencing of protocadherin 8 by promoter methylation, a candidate tumor suppressor for human gastric cancer. Oncol Rep, 2012; 28(5): 1785-91
35. He D, Zeng Q, Ren G et al: Protocadherin8 is a functional tumor suppressor frequently inactivated by promoter methylation in nasopharyngeal carcinoma. Eur J Cancer Prev, 2012; 21(6): 569-75
36. Narayan G, Xie D, Freddy AJ et al: PCDH10 promoter hypermethylation is frequent in most histologic subtypes of mature lymphoid malignancies and occurs early in lymphomagenesis. Genes Chromosomes Cancer, 2013; 52(11): 1030-41
37. Lin YL, Li ZG, He ZK et al: Clinical and prognostic significance of protocadherin-10 (PCDH10) promoter methylation in bladder cancer. J Int Med Res, 2012; 40(6): 2117-23
38. Li Z, Chim JC, Yang M et al: Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim Biophys Acta, 2012; 1823(2): 298-305
39. Imoto I, Izumi H, Yokoi S et al: Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. Cancer Res, 2006; 66(9): 4617-26
40. Haruki S, Imoto I, Kozaki K et al: Frequent silencing of protocadherin 17, a candidate tumour suppressor for esophageal squamous cell carcinoma. Carcinogenesis, 2010; 31(6): 1027-36